Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Doug Williams takes on CAR T cell access as TriArm CEO

Veteran of Biogen, Sana to head cross-border company TriArm Therapeutics

By Lauren Martz, Executive Director, Biopharma Intelligence
September 9, 2024 9:56 PM UTC

Cross-border infrastructure and a platform technology that supports broader CAR T cell access models have drawn biotech veteran Doug Williams to a new role as CEO of TriArm Therapeutics.

Williams was EVP and president of R&D at another cell therapy company, Sana Biotechnology Inc. (NASDAQ:SANA), until his recent departure, announced in April. He was co-founder and CEO of exosome company Codiak Biosciences Inc. (NASDAQ:CDAK) before joining Sana, and previously served as EVP of R&D at Biogen Inc. (NASDAQ:BIIB)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Sana Biotechnology Inc.

BCIQ Target Profiles

CD19